Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury.
Several attempts have been undertaken to reduce the severity of ischemic myocardial injury by exogenous administration of eicosanoids and by modification of endogenous eicosanoid production. The present study investigates whether defibrotide, a compound that stimulates endogenous prostacyclin (PGI2), has a beneficial effect in experimental ischemic myocardial injury. Anesthetized, open-chest minipigs were subjected to 1 h of coronary artery occlusion, followed by 3 h of reperfusion. Defibrotide (32 mg/kg x h) or its vehicle were infused i.v. throughout the experiment. Defibrotide increased cardiac PGI2 formation 3- to 4-fold greater than control (P < .05). Thromboxane levels remained unchanged. Irreversible ischemic injury, as identified by negative tetrazolium staining, amounted to 44 +/- 6% of the area at risk in pigs receiving vehicle but was reduced to 23 +/- 4% by defibrotide (P < .05). This reduced tissue injury in defibrotide-treated pigs was associated with improved functional recovery (left ventricular pressure, + dP/dtmax), during early reperfusion. Recovery did not occur in vehicle-treated pigs. Collagen (2 micrograms/ml)-induced platelet aggregation ex vivo was increased in vehicle-treated pigs during ischemia and reperfusion, but not in animals treated with defibrotide. Polymorphonuclear neutrophil leukocyte accumulation in the ischemic border zone was reduced from 59 +/- 17 cells/mm2 in vehicle-treated pigs to 17 +/- 9 cells/mm2 by defibrotide (P < .05). Pretreatment of the animals with indomethacin (3 mg/kg) prevented the reduction of infarct size and polymorphonuclear neutrophil leukocyte infiltration by defibrotide. Indomethacin increased infarct size in vehicle- and defibrotide-treated pigs by 71 and 59%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Hohlfeld
T
T
Institut für Pharmakologie, Heinrich-Heine Universität Düsseldorf, FRG.
Strobach
H
H
Schrör
K
K
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004195:Disease Models, Animal; D011464:Epoprostenol / Q000096:biosynthesis / Q000097:blood; D005260:Female; D006098:Granulocytes / Q000187:drug effects; D007213:Indomethacin / Q000494:pharmacology; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000517:prevention & control; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000517:prevention & control; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D010976:Platelet Count / Q000187:drug effects; D011089:Polydeoxyribonucleotides / Q000097:blood / Q000494:pharmacology*; D011453:Prostaglandins / Q000502:physiology*; D013268:Stimulation, Chemical; D013552:Swine; D013556:Swine, Miniature; D013928:Thromboxane A2 / Q000097:blood; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology
D016861:Cyclooxygenase Inhibitors; D011089:Polydeoxyribonucleotides; D011453:Prostaglandins; C036901:defibrotide; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D007213:Indomethacin